SECsense Logo

Lipella Pharmaceuticals Inc. 8-K Filing: Key Updates as of February 11, 2025

$LIPO
Form 8-K
Filed on: 2025-02-11
Source
Lipella Pharmaceuticals Inc. 8-K Filing: Key Updates as of February 11, 2025

Based on the provided section of the financial report, here are the key pieces of information extracted:

  1. Filing Information:
  • Company Name: Lipella Pharmaceuticals Inc.
  • CIK (Central Index Key): 0001347242
  • Filing Type: 8-K (a form used to report major events that shareholders should know about).
  • Filing Date: February 11, 2025.
  1. Company Details:
  • State of Incorporation: Delaware (DE).
  • SEC File Number: 005-93847.
  • EIN (Employer Identification Number): 20-2388040.
  • Address: 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208.
  • Contact Phone Number: (412) 894-1853.
  1. Stock Information:
  • Common Stock: The company has common stock with a par value of $0.0001 per share.
  • Stock Symbol: LIPO, traded on NASDAQ.
  1. Financial Reporting Context:
  • Reporting Period: The report references data as of February 11, 2025.
  1. Units of Measure:
  • Financial figures are reported in USD (United States Dollars) and shares.

Insights:

  • The filing indicates that Lipella Pharmaceuticals Inc. is active and compliant with SEC reporting requirements as demonstrated by the 8-K filing.
  • The information suggests the company may have important events or updates to communicate to its investors as of the filing date.
  • The company is publicly traded, which implies it is subject to regulations and scrutiny from both regulators and investors.
  • The presence of a specific par value for its common stock may be relevant for understanding its capital structure.

This information is critical for investors, analysts, and stakeholders who may be assessing the company's current status and future prospects.